Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues

David H. Coy, Chester Meyers, Akira Arimura, Andrew V. Schally, Tommie W. Redding

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Somatostatin was isolated from extracts of ovine1 and porcine2 hypothalamic tissue and was found to be a cyclic tetradecapeptide with the following sequence: {A figure is presented} Subsequent studies revealed that the peptide not only had inhibiting effects on growth hormone (GH) release, but also on pituitary thyrotropin (TSH) and a large array of gastrointestinal and pancreatic hormones, including insulin, glucagon, gastrin and gastric acid, secretin, CCK, GIP, VIP, and motilin. These activities have been recently reviewed.3. The therapeutic value of somatostatin in several important areas is diminished by its broad spectrum of activities. As with most naturally occurring peptides, somatostatin also has a short biologic half-life, 4 making its long-term use impractical. Therefore, analogues are being designed for enhanced, prolonged, and selective activities. In addition, competitive inhibitors of somatostatin could be of great interest and pharmacologic value.

Original languageEnglish (US)
Pages (from-to)1407-1410
Number of pages4
JournalMetabolism
Volume27
Issue number9 SUPPL. 1
DOIs
StatePublished - Sep 1978
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues'. Together they form a unique fingerprint.

  • Cite this